Pharmaceuticals

Eloxx Pharmaceuticals

Eloxx Pharma 于 2026 年 5 月 5 日 (美东时间) 发布了 FY2026 Q1 业绩，实际营收 0 USD，实际 EPS -0.8565 USD

Eloxx Pharma 于 2026 年 5 月 5 日 (美东时间) 发布了 FY2025 Q1 业绩，实际营收 0 USD，实际 EPS -4.94 USD

Eloxx Pharma released FY2025 Annual Earnings on March 17, 2026 (EST), with Actual Revenue of 0 USD and Actual EPS of -5.34 USD

Eloxx Pharma 于 2026 年 3 月 17 日 (美东时间) 发布了 FY2024 年度财报，实际营收 6.359 M USD，实际 EPS -9.1978 USD

Eloxx Pharma released FY2023 Annual Earnings on March 17, 2026 (EST): Revenue USD 0, EPS USD -72.976

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

Ticker Change

代码变更

From 2026.06.01 (EST) changed to ELOXD

ALHC

ELOX

RNAC

RGNT

Top biotech gainers on Tuesday included Regentis (RGNT), up 88% on knee repair implant updates; Eloxx (ELOX), soaring 77% after Nasdaq uplisting and public offering; Alignment Healthcare (ALHC), rising 25% on executive RSU grants and revenue guidance; and Cartesian Therapeutics (RNAC), gaining 16% via a strategic CAR-T licensing deal with WestGene.

rttnews

Alignment Healthcare

Cartesian Therapeutics

Regentis Biomaterials

Larimar Therapeutics

Top Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch

NUVL

During Tuesday's intraday session, several healthcare stocks experienced significant volatility. ELOXX Pharma surged 2364.9% to $9.12, while Regentis Biomaterials rose 128.9%. Other gainers included Nuvalent, Rafael Holdings, Cartesian Therapeutics, and Alignment Healthcare. Conversely, Aditxt plummeted 43.3%, with iTonic Holdings, AIM ImmunoTech, Bio Green Med Solution, HCW Biologics, and Icecure Medical also posting notable declines.

benzinga_article

Nuvalent

Rafael-B

Bio Green Med Solution

AIM ImmunoTech

Aditxt

Icecure Medical

HCW Biologics

iTonic

12 Health Care Stocks Moving In Tuesday's Intraday Session

Eloxx Pharmaceuticals announced the pricing of a $66.0 million public offering, selling 2,975,000 common shares at $11.00 and pre-funded warrants for up to 3,025,000 shares at $10.99. The company expects gross proceeds of $66.0 million before expenses. Trading on Nasdaq is expected to begin June 9, 2026, with closing anticipated on June 10, 2026. Leerink Partners and Guggenheim Securities are joint bookrunning managers.

StockTitan

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq | ELOX Stock News

ELOXD

Earnings Watch

ELOXX PHARMACEUTICALS INC

Eloxx Pharma | 10-Q: FY2026 Q1 Revenue: USD 0

Eloxx Pharmaceuticals(ELOX.US)

Top Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch

12 Health Care Stocks Moving In Tuesday's Intraday Session

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq | ELOX Stock News

Eloxx Pharma | 10-Q: FY2026 Q1 Revenue: USD 0

Trending